Naturally-occurring and recombinant forms of the aspartic proteinases plasmepsins I and II from the human malaria parasite Plasmodium falciparum  by Tyas, Lorraine et al.
FEBS Letters 454 (1999) 210-214 FEBS 22257 
Naturally-occurring and recombinant forms of the aspartic proteinases 
plasmepsins I and II from the human malaria parasite 
Plasmodium f alciparum 
Lorraine Tyas a, Ilya Gluzman b, Richard P. Moon c, Katharina Rupp c, Jennifer Westling d, 
Robert G. Ridley c, John Kay a, Daniel E. Goldberg b, Colin Berry a'* 
a Cardi~" School of Biosciences, Card([J' Univet~'ity, P.O. Box 911, Cardiff" CF1 3 US, UK 
b Howard Hughes Medical Institute, Departments of Molecular Microbiology and Medicine, Washington University School of Medicine, 
St. Louis', MO 631110, USA 
c F Hofjmann-La Roche, Pharmaceuticals Division, Pharma Research Preclinical, CH-4070 Basel, Switzerland 
d Department qf Biochemistry and Molecular Biology, University qf Florida, Gainesville, FL 32610, USA 
Received 20 April 1999: received in revised form 7 June 1999 
Abstract Comparable kinetic parameters were derived for the 
hydrolysis of peptide substrates and the interaction of synthetic 
inhibitors with recombinant and naturally-occurring forms of 
plasmepsin II. In contrast, recombinant plasmepsin I was 
extended by 12 residues at its N-terminus relative to its 
naturally-occurring counterpart and a 3-10-fold diminution in 
the kcat values was measured for substrate hydrolysis by the 
recombinant protein. However, comparable Ki values were 
derived for the interaction of two distinct inhibitors with both 
forms of plasmepsin I, thereby validating the use of recombinant 
material for drug screening. The value of plasmepsin I inhibitors 
was determined by assessing their selectivity using human 
aspartic proteinases. 
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1. Introduction 
Two aspartic proteinases (plasmepsin I and plasmepsin II) 
of the human malarial parasite Plasmodium falciparum play 
key roles in the essential pathway by which the parasites ca- 
tabolise up to 80% of host cell haemoglobin during the intra- 
erythrocytic stages of their life-cycle [12]. Inhibit ion of the 
plasmepsins (by pepstatin) results in a cessation of parasite 
growth leading to death [3]. Thus the aspartic proteinases 
represent excellent argets for the design of new anti-malarial 
drugs. 
Isolation of the naturally-occurring plasmepsins from the 
digestive vacuoles of the parasite in sufficient quantities to 
permit detailed investigations i impractical and therefore it 
has been necessary to produce each enzyme in recombinant 
form for initial characterisation [4,5]. Recombinant  plasmep- 
sin I appears to be more susceptible than recombinant plas- 
mepsin II to several inhibitors (e.g. Ro40-4388 and SC-50083) 
which have been demonstrated to be effective in preventing 
haemoglobin degradation and the growth of P. ,~dciparum in 
human red blood cells in culture [1,5]. Plasmepsin I was thus 
proposed as the primary drug target. 
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In order to validate whether recombinant forms of plas- 
mepsins I and II were appropriate for use in systematic inves- 
tigations into inhibitor design and development, it was con- 
sidered vital to establish that the properties of the 
recombinant enzymes, in terms of activity and specificity, re- 
flect those of their respective natural ly-occurring counterparts. 
2. Materials and methods 
2.1. Preparation and N-terminal sequencing of" recombinant [brms of 
plasmepshTs I and H 
Genes encoding a truncated zymogen of plasmepsin lI and an acti- 
vation site mutant of the plasmepsin I zymogen capable of autoacti- 
vation [5] were expressed in Escherichia coli and the resultant semi- 
proplasmepsins I and II that accumulated were refolded and purified 
as described previously [4,5]. The autoactivation f each semi-proplas- 
mepsin was carried out by mixing a sample of each purified prepara- 
tion with one tenth the volume of 1 M sodium formate buffer pH 4.4 
(1 M ionic strength), followed by incubation at 37°C for 30 rain. The 
proteins that resulted from each autoactivation were resolved on (sep- 
arate) 10% SDS-polyacrylamide g ls and blotted onto polyvinylidene 
difluoride (PVDF) membranes. N-terminal sequencing of each protein 
band was performed by automated Edman degradation using an Ap- 
plied Biosystems Protein Sequencer, model 476A (by courtesy of Dr. 
C.W. van den Berg, University of Wales College of Medicine, Cardiff, 
UK). 
2.2. Pur!/ieation qf naturally-occurring plasmepsin 1 and plasmepsin H 
Naturally-occurring plasmepsins I and II were isolated from the 
digestive vacuoles of P. jideiparum as described previously [2,6]. 
Each of these enzyme preparations was obtained alter hydroxylapatite 
chromatography and contained (respectively) the single proteolytic 
activity of either plasmepsin 1 or plasmepsin II without contamination 
by falcipain, the cysteine proteinase that is also present in the digestive 
vacuole [2]. 
2.3. Human aspartic proteinases 
Naturally-occurring human liver cathepsin D (Athens Research and 
Technology Inc., Athens, GA, USA), human gastricsin and human 
pepsin were prepared as previously described [7] whilst recombinant 
human cathepsin E was purified from E. coli as described by Hill et al. 
[8]. 
2.4. Spectrophotometric analysis of aspartic proteinase activity 
The hydrolysis of chromogenic substrates was monitored by follow- 
ing the decrease in absorbance at 300 nm using a Hewlett-Packard 
8452A diode array spectrophotometer. Initial velocities were meas- 
ured with at least six concentrations of each peptide substrate within 
an appropriate range in order to derive kinetic constants K,~ and 
Vmax. The estimated error for each parameter was always < 15%. 
The concentration f active enzyme [E] used in each assay was deter- 
mined by active site titration with isovaleryl pepstatin as described 
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previously [7,8] and values for kcat were calculated from the equation 
Vm~,x - kc~a [E]. 
Ki values were determined at pH 4.4 as described previously [7,8] 
using the chromogenic substrate Leu-Glu-Arg-Ile-Phe*Nph-Ser-Phe 
tbr the plasmepsJns [5] and Lys-Pro-lle-Glu-Phe*Nph-Arg-Leu for 
the human aspartic proteinases [7]. 
3. Results and discussion 
The recombinant and naturally-occurring forms of plas- 
mepsins I and II were assayed for their ability to hydrolyse 
five synthetic peptide substrates (Table l). Peptide 1 was 
based on the sequence surrounding the Phe-33-Leu-34 peptide 
bond in c~-globin which is cleaved to initiate haemoglobin 
degradation [6]; and peptides 2-5 form part of a rational 
series of substrates with single amino acid replacements. For 
both forms of plasmepsin II, similar values were derived for 
each of the kinetic parameters kcat ,  Km and kcat/Km with sub- 
strates 1 and 2 (Table 1). Thus, recombinant and naturally- 
occurring forms of plasmepsin II appeared to be exerting 
comparable activities. For this reason, peptides 3 5 were not 
examined with the naturally-occurring plasmepsin II since 
supplies of this form of this enzyme were severely limited. 
In contrast, the values measured for the specificity constants 
(kc~t/Km) for the hydrolysis of all five peptide substrates (Ta- 
ble 1) by recombinant plasmepsin I ranged from 3-10-fold 
lower than those determined for the naturally-occurring 
form of the enzyme. Closely similar Km values were detected 
with all substrates tested, however, so that the differences in 
kc~t/Km appear to originate predominantly in a disparity in the 
respective kcat values rather than in substrate binding affin- 
ities. 
This interpretation was further substantiated when the in- 
teraction of two peptide inhibitors was examined with the 
Ro40-4388 
O 
? 
( Ro40-5576 
Fig. 1. Inhibitory compounds. 
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Table 2 
Inhibition constants for the interaction of naturally-occurring and recombinant plasmepsins I and II with isovaleryl pepstatin and Ro40-4388 
Inhibitor Plasmepsin II Plasmepsin I 
Recombinant, Naturally occurring, Recombinant, Naturally occurring, 
Ki (nM) Ki (nM) Ki (nM) Ki (nM) 
Iva-Val-Val-Sta-Ala-Sta < 0.1 < 0.1 0.7 0.5 
Ro40-4388 500 500 4 9 
Assays were performed at 37°C in 0.1 M sodium formate buffer pH 4.4 with a final ionic strength of 0.1 M. Precise values for isovaleryl pep- 
statin with plasmepsin II could not be determined due to problems with mutual depletion relative to the concentration f plasmepsin 11 that 
needed to be included in the enzyme assay that was used. 
recombinant and naturally-occurring forms of plasmepsin I. 
Closely similar values for Ki were measured for both forms of 
plasmepsin I when the interaction was measured with either (i) 
a tight binding inhibitor (pepstatin), or (ii) a less potent in- 
hibitor (Ro40-4388) (Fig. l ; Table 2). Thus it would seem that 
binding of substrates and inhibitors (as reflected in Km and Ki 
respectively) is comparable in both recombinant and natu- 
rally-occurring forms of plasmepsin I and therefore it would 
appear to be justifiable to use the recombinant form of plas- 
mepsin I in studies to enable the design and development of
novel inhibitors as anti-malarial drugs. However, the effi- 
ciency of substrate cleavage (as reflected in kcat and kcat/Km) 
does appear to be compromised in the recombinant form of 
plasmepsin I relative to the naturally-occurring form. This 
effect is unlikely to be due to differential glycosylation of 
recombinant and naturally-occurring forms since recent stud- 
ies have shown that the plasmepsins are not glycosylated [9]. 
A somewhat similar situation has been described previously 
[10] for the human aspartic proteinase precursor, procathepsin 
D. Upon exposure to acid in vitro, this zymogen undergoes 
self-processing to generate an activation intermediate (called 
pseudocathepsin D) which is incapable of further autocleav- 
age to generate the mature form of cathepsin D (an extrinsic 
enzyme activity is required for this purpose). Nevertheless, 
pseudocathepsin D is active towards peptide substrates but 
it has been shown to have kca t values that are lowered relative 
to those of mature cathepsin D. It retains 18 of the propart 
residues that should normally be removed uring the activa- 
tion process and thus consists of mature cathepsin D extended 
at its N-terminus by a further 18 residues (Fig. 2). 
Edman degradation of the recombinant form of plasmepsin 
1 through 16 cycles generated the unequivocal sequence: Phe- 
Lys-Thr-Gly-Leu-Thr-Gln-Lys-Pro-His-Leu-Gly-Asn-Ala-Gl- 
y-Asp ~.  
The parts of the sequence shown in bold represent the 
N-terminal residues that were reported previously for the 
naturally-occurring form of the mature enzyme that was iso- 
lated from the digestive vacuoles of P. Jalciparum [2]. Thus, 
the recombinant plasmepsin I that was generated by auto- 
activation under acid conditions (pH 4.4) in vitro of the 
(mutant) semi-proplasmepsin I precursor appears to be longer 
than its natural counterpart by 12 residues. 
How would the 12 remaining residues of the propart of 
plasmepsin I affect its activity relative to naturally-occurring 
plasmepsin 1? In the crystal structures of porcine pepsinogen 
[11] and human progastricsin [12], a conserved Lys residue at 
position 36P in the propart appears to interact electrostati- 
cally via its positively charged side chain with the carboxylate 
groups of the two catalytic Asp residues. In pseudocathepsin 
D, gys-36P is one of the residues which remains attached to 
the partially-activated form of the enzyme. It is located 11 
residues upstream of the authentic N-terminus and continued 
interaction of this residue with the catalytic apparatus has 
been postulated to contribute to the lower kcat values meas- 
ured for pseudocathepsin D [10]. Alignment of the extended 
N-termini of pseudocathepsin D and the activated recombi- 
nant plasmepsins generated in this study (Fig. 2) shows that, 
like pseudocathepsin D, recombinant plasmepsin I has a Lys 
residue 11 amino acids upstream of the authentic N-terminus 
of the naturally-occurring protein. This may well be in a po- 
sition to be involved in interactions at the active site resulting 
in the decrease that was observed in the kcat values measured 
for the recombinant form of plasmepsin I. 
For comparative purposes, the N-terminal sequence of re- 
combinant plasmepsin II (produced correspondingly b  au- 
toactivation of the semi-proplasmepsin II precursor at pH 
4.4) was also determined and two overlapping sequences 
were detected. The major sequence (62%) was found to be 
Leu- Gly- Ser-Ser-Asn-Asp-Asn-Ile- Glu-Leu-Val-Asp-Phe-Gln- 
Asn~ whilst the second sequence (38%) was Leu-Asn-Ser- 
Gly-Leu-Thr-Lys-Thr-Asn-Tyr-Leu-Gly-Ser-Ser-Asn-Asp ~.  
In both cases, the bold sequence represents he N-terminus of 
mature plasmepsin II as reported for the enzyme isolated from 
P..fah:iparum [2]. Thus, following autoactivation of the re- 
combinant semi-proplasmepsin II precursor at pH 4.4 in vitro, 
the predominant form of recombinant plasmepsin II produced 
was closely similar to its naturally-occurring counterpart, 
being longer at its N-terminus by just two residues. However, 
PM I: Phe-Lvs-Thr-Gly-Leu-Thr-Gln-Lys-Pro-His -Leu-Gly-Asn-Ala-  
PM II: Leu-Asn-Ser-Gly-Leu-Thr-Lys-Thr-Asn-Tyr-Leu-Gly-Ser-Ser~ 
Ps CatD: I le-Ala-Lys-Gly- Pro-Val-Ser-Lvs-Tyr- Ser-Gln-Ala-Val  -Pro-Ala-Va I -Thr-GIu-GIY- Pro- 
Fig. 2. Alignment of the extended N-termini of autoactivated recombinant forms of plasmepsin I and plasmepsin 1!with that of human pseu- 
docathepsin D. N-terminal sequences are shown for the autoactivated form of recombinant plasmepsin I (PM I), the longer activation product 
of recombinant plasmepsin II (PM II) and pseudocathepsin D (Ps CatD). Residues corresponding to the N-termini of the naturally-occurring 
forms of each enzyme are shown in bold. Lys-36P of pseudocathepsin D and equivalent residues in the plasmepsins are underlined. 
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Table 3 
Interaction of four inhibitor compounds with the recombinant plasmepsins and the human aspartic proteinases cathepsin D, cathepsin E, pepsin 
and gastricsin 
Inhibitor Plasmepsin I, Plasmepsin II, Cathepsin D, Cathepsin E, Pepsin, Gastricsin, 
Ki (nM) K i (nM) Ki (nM) Ki (nM) I£ i (nM) Ki (nM) 
Ro40-4388 4 500 70 400 8000 > 20 000 
Ro40-5576 6 250 2000 5000 3000 5000 
Measurements were performed at 37°C with the ionic strength maintained at 0.1 M. Individual assay conditions were as follows: (i) Recombi- 
nant plasmepsins I and I1; 0.1 M sodium formate buffer pH 4.4. (ii) Recombinant human cathepsin E and naturally-occurring human cathepsin 
D, pepsin and gastricsin; 0.1 M sodium formate buffer pH 3.1. 
a minor (longer) form, similar in length to the recombinant 
form of plasmepsin I, was also found to be present in the 
mixture. In the 12 residue extension of this longer form of 
plasmepsin II, a lysine residue is not found at the correspond- 
ing position to that of recombinant plasmepsin I and pseudo- 
cathepsin D (Fig. 2). Instead, an uncharged Asn residue re- 
places the Lys-36P, thus precluding any detrimental 
interactions with the residues of the catalytic apparatus. 
Thus, it is perhaps not surprising that the kinetic parameters 
measured for substrate hydrolysis (Table 1) and the binding of 
the two inhibitors, isovaleryl pepstatin and Ro40-4388 (Table 
2) are closely similar for both recombinant and naturally-oc- 
curring forms of plasmepsin II. 
Since the activity of recombinant plasmepsin II can be tak- 
en as representative of its naturally-occurring counterpart, the 
data in Table 1 also allow comparison of this plasmepsin II 
with naturally-occurring plasmepsin I. The haemoglobin- 
based substrate (peptide 1) is hydrolysed readily by natu- 
rally-occurring plasmepsin I and both forms of plasmepsin 
II. When kinetic constants are compared between recombi- 
nant plasmepsin lI and naturally-occurring plasmepsin I for 
a series of peptides [2 5] small differences in specificity 
emerge. When the aromatic Phe in the P3 position of pcptide 
2 is replaced by a Leu, the kcat for plasmepsin I decreases 3- 
fold whereas the kc~,t for plasmepsin II decreases by less than 
2-fold with the result that in terms of the specificity constant 
(kcat/Km), recombinant plasmepsin II is more than twice as 
efficient at hydrolysing peptide 3 than naturally-occurring 
plasmepsin I. 
When the Val in the P2 position in peptide 2 is replaced by 
Asn (peptide 4), there is a 2-fold decrease in the value of kcat/ 
Km obtained with naturally-occurring plasmepsin I. This is in 
contrast o an 8-fold drop apparent for plasmepsin lI. Thus, 
in terms of kcat/Kln values, naturally-occurring plasmepsin I is 
three times more effective at hydrolysing this substrate with a 
P2 Asn substituent than plasmepsin II. These differences in 
substrate specificity can be rationalised by reference to the 
molecular model of plasmepsin I [5] and the crystal structure 
of plasmepsin II [13] which indicate that plasmepsin I has 
larger $3 and $2 subsites, and is better able to accommodate 
P3 Phe and P2 Asn residues than plasmepsin if. 
This distinction i  subsite requirements for the hydrolysis of 
substrates was also reflected in the susceptibility of both en- 
zymes to inhibition. The general aspartic proteinase inhibitor 
isovaleryl pepstatin is highly potent against naturally-occur- 
ring plasmepsin H and less active against naturally-occurring 
plasmepsin I (Table 2). The converse is true for the inhibitor 
Ro40-4388 which has at least a 50-fold higher affinity for 
plasmepsin I than for plasmepsin II. For each inhibitor the 
Ki value measured for recombinant plasmepsin II was indis- 
tinguishable from that calculated for its naturally-occurring 
counterpart (Table 2). In addition, despite the complexities 
described above for specificity constants of naturally-occur- 
ring and recombinant plasmepsin I, comparable values were 
measured for both forms of this enzyme. 
To consider compounds uch as Ro40-4388 as leads for 
drug developments, selectivity for the target enzyme is essen- 
tial. Thus, the selectivity of Ro40-4388 was assessed by exam- 
ining its ability to inhibit the well-documented human aspartic 
proteinases cathepsin D, cathepsin E, pepsin and gastricsin 
(Table 3). Ro40-4388 is a good inhibitor of plasmepsin I (Ta- 
ble 2; [5]) but it also has a relatively poor selectivity since the 
Ki that was measured against cathepsin D was only approx- 
imately 17-fold poorer than that determined for plasmepsin I 
(and its affinity for both cathepsin D and cathepsin E was 
greater than for plasmepsin II (Table 3)). Therefore, a second 
compound Ro40-5567, which inhibited plasmepsin I with effi- 
ciency comparable to Ro40-4388, was tested with the human 
enzymes (Table 3). This inhibitor shows at least a 300-fold 
greater affinity for plasmepsin l than for any of the human 
enzymes. Although this would be considered insufficient selec- 
tivity for a drug, it nonetheless represents a considerable im- 
provement over Ro40-4388. Ro40-5567 has also been shown 
to kill parasites in culture [5], thus an understanding of its 
interaction with plasmepsin I may be useful in the future 
development of plasmepsin i hibitors as drugs. 
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